Zogenix (NASDAQ:ZGNX) issued its quarterly earnings results on Tuesday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.17), Bloomberg Earnings reports. Zogenix had a negative net margin of 309.76% and a negative return on equity of 81.65%. During the same quarter last year, the company earned ($0.95) earnings per share.
Shares of Zogenix (ZGNX) remained flat at $$44.50 during trading on Wednesday. The company had a trading volume of 211,756 shares, compared to its average volume of 602,236. The stock has a market cap of $1,530.00, a P/E ratio of -12.63 and a beta of 1.57. Zogenix has a 52 week low of $10.00 and a 52 week high of $45.85.
A number of research firms have commented on ZGNX. Leerink Swann reaffirmed an “outperform” rating on shares of Zogenix in a research note on Sunday, March 4th. Mizuho reiterated a “buy” rating and issued a $51.00 target price on shares of Zogenix in a report on Wednesday, March 7th. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub upgraded Zogenix from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. Finally, JMP Securities began coverage on Zogenix in a report on Monday, November 27th. They issued an “outperform” rating and a $56.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $46.40.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.